Dr. rer. nat. Anna Christina Dragon, Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School (MHH); nextGENERATION Medical Scientist Program, Hannover Medical School (MHH); national Translational Tandem Program for Gene- and Cell-based Therapies (nTTP-GCT), Berlin

Dr. Anna Christina Dragon is Postdoctoral Scientist in the research group of Prof. Dr. Britta Eiz-Vesper in the Focus Cellular Immunotherapy at the Institute of Transfusion Medicine and Transplant Engineering (ITT) of Hannover Medical School (MHH).

Her projects in the field of adoptive cellular immunotherapy focus on the development, optimization, and large-scale manufacturing of genetically modified T cells as therapy for different diseases.

With the use of innovative strategies involving T cells engineered with chimeric antigen receptors (CARs) or CAR-like receptors, her research aims are to develop novel treatment options for hematological and solid tumors, (malignant) virus-associated diseases, and to prevent transplant rejection following solid organ transplantation (SOT) with the strong rationale to translate findings into clinical application.

 

Within the gene and cell therapy field, Dr. Dragon is most interested in T cells engineered with CARs or CAR-like receptors and how they can optimized by further modification or equipment.


RESEARCH AREAS

  • Cellular Immunotherapy
  • T-Cell Engineering
  • CAR-T Cells
  • Cancer
  • Transplant Immunology

 

 

 

 

 

 

CONTACT

Dr. Anna Christina Dragon

Institute of Transfusion Medicine and Transplant Engineering

Hannover Medical School

Feodor-Lynen-Str. 5

30625 Hanover, Germany

+49 511 532 9819

dragon.anna@mh-hannover.de

PubMed Link https://www.ncbi.nlm.nih.gov/myncbi/anna%20christina.dragon.1/bibliography/public/